Syndax社は、再発・難治性のNPM1変異、KMT2変異、およびNUP98変異を有する急性骨髄性白血病(AML)の治療薬として、Revuforj®(レブメニブ)とデシタビン/シダザリルおよびベネトクラクスを併用した治療に関するSAVE試験のデータが『Journal of Clinical Oncology』誌に掲載されたと発表した。—GlobeNewswire
Syndax社は、再発・難治性のNPM1m、KMT2Ar、およびNUP98r AMLの治療における、Revuforj®(レブメニブ)とデシタビン/シダゾリジンおよびベネトクラクスの併用療法に関するSAVE試験のデータを、*Journal of Clinical Oncology*誌に掲載したと発表した。(GlobeNewswire)
该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Produtos relacionados com este artigo
Estes produtos foram associados automaticamente a partir do titulo, resumo e conteudo do artigo.
Perguntas frequentes
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Quizartinib – Compre online Lucius Anagrelide – Compre online Lucius Tazemetostat – Compre online Lucius Acalabrutinib – Compre online.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.